Dr. Surekha S

Telangana State Medical Council,Registration Number :58941( 2007)

Doctor can fluently Speaks English, Hindi, Telugu, Kanada, Tamil and Urdu and can understand all South and North Indian Languages

Rs. 1500/- for first appointment or newly registered patitent; Rs. 1000/- for follow-up review patitent.

All insurance plans are accepted; however, Asha Hospital does not offer a cashless facility. Insurance acceptance is subject to the terms and conditions of the policy issuer. Please verify coverage details with your insurance provider before addmission.

MBBS from Sri Devaraj Urs Medical College, Kolar, Karnataka
MD in Psychiatry from Bhaskar Medical College, Hyderabad
Fellowship in Psychosexual Medicine from JSS Medical College, Mysore

Dr. Surekha S. has over 12 years of experience in the healthcare field, with a strong foundation in both general and specialized medical services.

She has dedicated 9 years to the field of Psychiatry, where she has successfully treated a wide range of mental health conditions with empathy and clinical precision.

In addition, she has 3 years of focused experience in Psychosexual Medicine, addressing complex issues related to sexual health and therapy.

Her multidisciplinary expertise enables her to deliver holistic and patient-centered care, combining medical knowledge with compassionate support.

Member of the Indian Psychiatric Society (IPS)
Member of the Indian Medical Association (IMA)
Member of the Telangana Psychiatric Society
Member of the Hyderabad Psychiatric Society

CONFERENCE PRESENTATIONS

Poster Presentation Deceptive Green, ANCIPS 2017
Female Infertility Symposium WCAP 2022

CLINICAL TRAILS

1. A Randomized, Open-Label, Two-Way Crossover, Multiple-Dose, Comparative Bioavailability Study of Aripiprazole Extended-Release Injectable Suspension (400 mg) (Apotex Inc.) Versus Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension (400 mg) (Otsuka America Pharmaceutical, Inc.) (USA) in Patients with Schizophrenia (C2A01730)

2. A Randomised, Open-Label, Two-Treatment, Two-Sequence, Full-Replicate, Multicenter, Multiple-Dose, Steady-State Crossover, Bioequivalence Study of Aripiprazole for Extended-Release Injectable suspension for intramuscular use 400 mg (Single dose vial) of Pharmathen S.A. Compared to Abilify Maintena 400 mg Powder and Solvent for Prolonged-Release Suspension for Injection of Otsuka Pharmaceutical Netherlands B.V., Netherlands in Adult Patients with Schizophrenia. (C2A01319)


3. A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Multicenter, Multiple-Dose, Steady-State, Crossover, Bioequivalence Study of Aripiprazole Extended Release Injectable Suspension 400 mg/vial of Sun Pharmaceutical Industries Limited Compared to ABILIFY MAINTENA® 400 mg/vial of Otsuka America Pharmaceutical Inc., USA in Adult Patients with Schizophrenia under Fasting Condition (Version 3.0, 13 Oct 2021) (C2A00692)


4. A Randomized, Multicentre, Multiple-dose, Two-treatment, Single period, Parallel, Steady-State Bioequivalence Study of Mylan’s Paliperidone Prolonged-Release Injectable Suspension 100 mg and Xeplion® 100 mg of Janssen-Cilag Ltd in Subjects with Schizophrenia under Fasting Condition (PALI-ISR-1001)


5. A Randomized, Multicenter, Single-dose, Two-treatment, Single-period, Parallel, Bioequivalence Study of Mylan’s Paliperidone Prolonged release Suspension for Injection, 175 mg and Janssen-Cilag’s Trevicta® prolonged release suspension for injection, 175 mg in Subjects with Schizophrenia. (PALI-ISR-1003)

6. An Open Label, Prospective, Multicenter, Post marketing Surveillance (Phase IV) Study to Evaluate the Safety, Tolerability, and Efficacy of Lemborexant in Adult Subjects (Age 18 - 65 Years) With Insomnia in India. (E2006-M091-503)

7. A prospective, multicenter study of endoxifen in the treatment across the bipolar I mood spectrum, from mania with or without depressive symptoms to depression with or without manic symptoms in clinical practice setting.( 0124-21 )


8. A Prospective, Multicenter Study to Evaluate Real- world Effectiveness and Safety of Endoxifen as a maintenance treatment in Patients of bipolar I mood spectrum, from mania with or without depressive symptoms to depression with or without manic symptoms in clinical practice setting.( 0125-21)

9. A prospective, randomised, double-blind, multicenter comparative study to Evaluate the Efficacy, Safety and Pharmacokinetics of Cannabidiol oral solution versus matching Placebo for treatment of mild to moderate anxiety disorders. (CP-CBD001-22)

10. A randomized, double-blind, placebo controlled, parallel study to determine safety and efficacy of the Cannabidiol (VL-SE-01) in healthy participants CP-CBD001-22 (PK Study)

11. An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication. (NW-3509/015/II/2019)

12. Open-Label, Randomized, Multiple-Dose, Two-Treatment, Reference-Replicate, Crossover, Steady State Relative Bioavailability Study of Lupin Risperidone Long-Acting Injection Compared with Risperdal Consta® (Risperidone) Long-Acting Injection in Adult Male and Female Patients with Schizophrenia. (RC-GX-103)


CONFERENCES ORGANISED

NATIONAL AND INTERNATIONAL CONFERENCES
WCAP2022
ANCIPS 2025

1. What is Dr. Surekha S’s availability?
Dr. Surekha S is available for consultations during her designated OPD hours at Asha Hospital, Banjara Hills, Hyderabad. To ensure timely consultation and avoid waiting, it is recommended to book a prior appointment unless it is an emergency.

2. What conditions does Dr. Surekha S specialize in treating?
Dr. Surekha specializes in both sexual health and general psychiatric conditions. Her expertise in sexual health includes treating erectile dysfunction, premature ejaculation, performance anxiety, arousal disorders, vaginismus, unconsummated marriage, porn addiction, sexual abuse trauma, and sexual health concerns among LGBTQ+ individuals. She also offers sex education, pre- and post-marital counselling, relationship counselling, and sex therapy. In general psychiatry, she manages conditions such as schizophrenia, bipolar mood disorder, major depressive disorder, obsessive-compulsive disorder (OCD), anxiety disorders, and substance addictions.

3. What services are offered at the Asha Sexual Wellness Clinic?
At Asha Sexual Wellness Clinic, Dr. Surekha provides a holistic range of services including pharmacotherapy, individual and couple counselling, neuromodulation therapies, and personalized treatment plans. These services are aimed at promoting patient recovery, improving mental and sexual well-being, and enabling social reintegration.

4. Is counselling part of the treatment?
Yes, counselling is a key component of the treatment approach offered by Dr. Surekha S. It plays a vital role in helping individuals understand and overcome their psychological and emotional challenges through structured support and therapeutic techniques.

5. How can I schedule an appointment with Dr. Surekha S?
You can schedule an appointment by contacting the Asha Hospital helpline directly or visiting the official website, where online booking options are available for your convenience.